Cargando…

Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease

Vogt-Koyanagi-Harada (VKH) disease is a rare and serious ocular adverse reaction following COVID-19 vaccination. This study aimed to evaluate the clinical features, diagnosis and management of COVID-19 vaccine-associated VKH disease. Case reports of VKH disease after COVID-19 vaccination were collec...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ke, Gao, Bingqian, Li, Jiayi, Xiang, Yixin, Cao, Lin, Zhao, Mingyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305503/
https://www.ncbi.nlm.nih.gov/pubmed/37282614
http://dx.doi.org/10.1080/21645515.2023.2220630
_version_ 1785065749680750592
author Xu, Ke
Gao, Bingqian
Li, Jiayi
Xiang, Yixin
Cao, Lin
Zhao, Mingyi
author_facet Xu, Ke
Gao, Bingqian
Li, Jiayi
Xiang, Yixin
Cao, Lin
Zhao, Mingyi
author_sort Xu, Ke
collection PubMed
description Vogt-Koyanagi-Harada (VKH) disease is a rare and serious ocular adverse reaction following COVID-19 vaccination. This study aimed to evaluate the clinical features, diagnosis and management of COVID-19 vaccine-associated VKH disease. Case reports of VKH disease after COVID-19 vaccination were collected up to February 11, 2023 for retrospective analysis. Twenty-one patients (9 males and 12 females) were included, with a median age of 45 years (range 19–78), from three main regions, Asia (12/21), the Mediterranean region (4/21), and South America (5/21). Fourteen patients developed symptoms after the first dose of the vaccine, and 8 after the second dose. Vaccines included mRNA vaccine (10 cases), virus vector vaccine (6 cases), and inactivated vaccine (5 cases). The average time interval from vaccination to onset of symptoms was 7.5 days (range 12 hours to 4 weeks). All 21 patients experienced visual impairment after vaccination, with 20 cases involving both eyes. Sixteen patients showed symptoms of meningitis. Serous retinal detachment was observed in 16 patients, choroidal thickening was observed in 14, aqueous cell in 9, and subretinal fluid in 6. CSF pleocytosis was detected in 7 patients and skin symptoms were found in 3 patients. All patients received corticosteroid therapy, and 8 also received immunosuppressive agents. All patients recovered well, with a mean recovery time of 2 months. Early diagnosis and early treatment are crucial to the prognosis of patients with VKH after vaccination with COVID-19 vaccine. The risk of vaccination against COVID-19 in patients with a history of VKH disease should be evaluated clinically.
format Online
Article
Text
id pubmed-10305503
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-103055032023-06-29 Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease Xu, Ke Gao, Bingqian Li, Jiayi Xiang, Yixin Cao, Lin Zhao, Mingyi Hum Vaccin Immunother Coronavirus Vogt-Koyanagi-Harada (VKH) disease is a rare and serious ocular adverse reaction following COVID-19 vaccination. This study aimed to evaluate the clinical features, diagnosis and management of COVID-19 vaccine-associated VKH disease. Case reports of VKH disease after COVID-19 vaccination were collected up to February 11, 2023 for retrospective analysis. Twenty-one patients (9 males and 12 females) were included, with a median age of 45 years (range 19–78), from three main regions, Asia (12/21), the Mediterranean region (4/21), and South America (5/21). Fourteen patients developed symptoms after the first dose of the vaccine, and 8 after the second dose. Vaccines included mRNA vaccine (10 cases), virus vector vaccine (6 cases), and inactivated vaccine (5 cases). The average time interval from vaccination to onset of symptoms was 7.5 days (range 12 hours to 4 weeks). All 21 patients experienced visual impairment after vaccination, with 20 cases involving both eyes. Sixteen patients showed symptoms of meningitis. Serous retinal detachment was observed in 16 patients, choroidal thickening was observed in 14, aqueous cell in 9, and subretinal fluid in 6. CSF pleocytosis was detected in 7 patients and skin symptoms were found in 3 patients. All patients received corticosteroid therapy, and 8 also received immunosuppressive agents. All patients recovered well, with a mean recovery time of 2 months. Early diagnosis and early treatment are crucial to the prognosis of patients with VKH after vaccination with COVID-19 vaccine. The risk of vaccination against COVID-19 in patients with a history of VKH disease should be evaluated clinically. Taylor & Francis 2023-06-06 /pmc/articles/PMC10305503/ /pubmed/37282614 http://dx.doi.org/10.1080/21645515.2023.2220630 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
spellingShingle Coronavirus
Xu, Ke
Gao, Bingqian
Li, Jiayi
Xiang, Yixin
Cao, Lin
Zhao, Mingyi
Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease
title Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease
title_full Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease
title_fullStr Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease
title_full_unstemmed Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease
title_short Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease
title_sort clinical features, diagnosis, and management of covid-19 vaccine-associated vogt-koyanagi-harada disease
topic Coronavirus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305503/
https://www.ncbi.nlm.nih.gov/pubmed/37282614
http://dx.doi.org/10.1080/21645515.2023.2220630
work_keys_str_mv AT xuke clinicalfeaturesdiagnosisandmanagementofcovid19vaccineassociatedvogtkoyanagiharadadisease
AT gaobingqian clinicalfeaturesdiagnosisandmanagementofcovid19vaccineassociatedvogtkoyanagiharadadisease
AT lijiayi clinicalfeaturesdiagnosisandmanagementofcovid19vaccineassociatedvogtkoyanagiharadadisease
AT xiangyixin clinicalfeaturesdiagnosisandmanagementofcovid19vaccineassociatedvogtkoyanagiharadadisease
AT caolin clinicalfeaturesdiagnosisandmanagementofcovid19vaccineassociatedvogtkoyanagiharadadisease
AT zhaomingyi clinicalfeaturesdiagnosisandmanagementofcovid19vaccineassociatedvogtkoyanagiharadadisease